Dave Gancarz | BiotechTV

top of page

SF Healthcare Week: Summit Therapeutics has filed for approval on the first indication of its PD1 x VEGF. Will it live up to its promise and set the next standard for cancer care?

Biotech veteran and Summit Chairman Bob Duggan and Summit's Chief Strategy and Business Officer Dave Gancarz discuss the filing, and discuss trying to stay out front and on top in this emerging new class of medicines.

Company News

4 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

SF Healthcare Week: Summit Therapeutics has filed for approval on the first indication of its PD1 x VEGF. Will it live up to its promise and set the next standard for cancer care?

Follow BiotechTV

Sponsors

Sponsor Spotlight